Business Wire

CA-NETAPP

Share
Aston Martin Aramco Formula One® Team and NetApp Renew Partnership

The Aston Martin Aramco Formula One® Team and NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the renewal of their partnership, designating NetApp as the team’s Global Data Infrastructure Partner. NetApp has been a key partner to the team since it returned to Formula One® racing in 2021 after more than 60 years away from the track. This partnership renewal builds on the previous three years of successful collaboration, empowering Aston Martin Aramco to use NetApp’s storage technology to instantly store, manage, and access the immense amounts of data the team needs to optimize its performance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240205989417/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Clare Lansley (left), CIO of Aston Martin Aramco and George Kurian (right), CEO of NetApp, shake hands to celebrate their companies’ partnership renewal. (Photo: Business Wire)

Data gives Formula One® drivers and their support teams the insights they need to make the right decisions to optimize their race performance. Data powers simulations that help teams predict and respond to scenarios that might occur during a race such as changing weather conditions or an unplanned pit stop. Using data to understand the impact of these situations in advance enables them to adapt in real-time in a race where milliseconds matter. Without those insights, the teams might not make a decision about how to respond before the opportunity has passed by. During any race, the Aston Martin Aramco team collects data from hundreds of sensors, including real-time performance statistics such as track temperature, tire degradation, and aerodynamics. Instant access to that data, both trackside and at the team’s state-of-the-art AMR Technology Campus (AMRTC), gives the team the data it needs to adapt its race strategy in real-time. Since sharing data between the track and team headquarters plays such a central role in the team’s success, data storage and management is a mission-critical function.

“We are delighted to renew our partnership with NetApp as we enter our fourth season together since returning to Formula One in 2021,” said Clare Lansley, CIO of Aston Martin Aramco. “NetApp has been with us all the way on this journey together and are fundamental to our trackside operations and at our Headquarters at the AMRTC in Silverstone. We use data to improve our performance and go faster and NetApp’s work with the team is vital to this success.”

By leveraging the data NetApp stores and manages, the Aston Martin Aramco team reached the podium eight times, scored 280 points, and finished fifth in the Constructors’ Championship in the 2023 Formula One® season. By having NetApp as its Global Data Infrastructure Partner, the team will receive continued support for its data storage and analysis including:

  • Speed: The NetApp FlexPod® data center solution helps the team instantly access and store immense amounts of data, transferring data quickly and efficiently between trackside, race headquarters, and the factory to enable near-real time decisions that affect race strategy.
  • Reliability: NetApp® Cloud Volumes ONTAP® ensures enterprise reliability and continuous operations in case of failures, so the team’s data is always there when it needs it.
  • Observability: NetApp® Cloud Insights makes it easy for the team to monitor, troubleshoot, and optimize all its resources and applications so it can efficiently adopt and operate new technology both on premises and in the cloud, providing full-stack observability.
  • Security: NetApp® Storage Workload Security provides continuous protection against both insider and external threats by monitoring and protecting the data held on the NetApp platform.
  • Scalability: The entire NetApp solution can scale and grow so the team can rise to any challenge even as its IT requirements grow and change.

“NetApp and the Aston Martin Aramco team are well matched as partners because we are both dedicated to the pursuit of breakthrough performance and true innovation,” said Gabie Boko, Chief Marketing Officer at NetApp. “When Aston Martin returned to the Formula One® circuit after more than 60 years away, they needed a technology partner to help them rise to every moment, both on and off the track. NetApp provides Aston Martin Aramco with an intelligent data infrastructure that runs at the speed of Formula One®.”

The sheer speed at which Aston Martin Aramco can harness its stored data gives it a clear competitive advantage. NetApp data solutions enable the team to fuel its relentless pursuit of innovation as it designs faster vehicles and optimizes its race strategy.

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240205989417/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye